JP2017509611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509611A5 JP2017509611A5 JP2016553397A JP2016553397A JP2017509611A5 JP 2017509611 A5 JP2017509611 A5 JP 2017509611A5 JP 2016553397 A JP2016553397 A JP 2016553397A JP 2016553397 A JP2016553397 A JP 2016553397A JP 2017509611 A5 JP2017509611 A5 JP 2017509611A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- cycloalkyl
- pharmaceutically acceptable
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- -1 4,5-dimethyloxazol-2-yl Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- 102000005600 Cathepsins Human genes 0.000 claims 1
- 108010084457 Cathepsins Proteins 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000027004 Eosinophilic disease Diseases 0.000 claims 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 claims 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 claims 1
- 102000002255 Secretory Proteinase Inhibitory Proteins Human genes 0.000 claims 1
- 108010000303 Secretory Proteinase Inhibitory Proteins Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000003454 betamimetic effect Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000003591 leukocyte elastase inhibitor Substances 0.000 claims 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 0 CCc1ccc(*)cc1 Chemical compound CCc1ccc(*)cc1 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14156159.7 | 2014-02-21 | ||
| EP14156159 | 2014-02-21 | ||
| PCT/EP2015/053309 WO2015124563A1 (en) | 2014-02-21 | 2015-02-17 | Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509611A JP2017509611A (ja) | 2017-04-06 |
| JP2017509611A5 true JP2017509611A5 (enExample) | 2018-03-29 |
| JP6434528B2 JP6434528B2 (ja) | 2018-12-05 |
Family
ID=50137570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553397A Active JP6434528B2 (ja) | 2014-02-21 | 2015-02-17 | 置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9221807B2 (enExample) |
| EP (1) | EP3107911B1 (enExample) |
| JP (1) | JP6434528B2 (enExample) |
| WO (1) | WO2015124563A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017207433A1 (en) * | 2016-05-31 | 2017-12-07 | Chiesi Farmaceutici S.P.A. | Hetetocyclic compounds for use in the treatment of a disease in which hne is implicated |
| EP3464268B1 (en) * | 2016-05-31 | 2020-03-11 | Chiesi Farmaceutici S.p.A. | Novel compounds |
| WO2020114947A1 (en) * | 2018-12-03 | 2020-06-11 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as vanin inhibitors |
| WO2021053058A1 (en) | 2019-09-17 | 2021-03-25 | Mereo Biopharma 4 Limited | Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease |
| LT4106757T (lt) | 2020-04-16 | 2023-11-10 | Mereo Biopharma 4 Limited | Neutrofilų elastazės inhibitoriaus alvelestato panaudojimas kvėpavimo sistemos ligų, nulemtų alfa-1 antitripsino nepakankamumo, gydymui |
| JP2024505073A (ja) * | 2021-01-29 | 2024-02-02 | ダイアメディカ ユーエスエー インコーポレイテッド | 疾患を処置するためのウリナスタチンポリペプチド |
| JP2024540952A (ja) | 2021-10-20 | 2024-11-06 | メレオ バイオファーマ ４ リミテッド | 線維化の治療における使用のための好中球エラスターゼ阻害剤 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200500341A (en) * | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| SE0302487D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0605469D0 (en) * | 2006-03-17 | 2006-04-26 | Argenta Discovery Ltd | Multimers of heterocyclic compounds and their use |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| RU2012116877A (ru) | 2009-10-02 | 2013-11-10 | Астразенека Аб | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы |
-
2015
- 2015-02-12 US US14/620,323 patent/US9221807B2/en active Active
- 2015-02-17 WO PCT/EP2015/053309 patent/WO2015124563A1/en not_active Ceased
- 2015-02-17 EP EP15705807.4A patent/EP3107911B1/en active Active
- 2015-02-17 JP JP2016553397A patent/JP6434528B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015526453A5 (enExample) | ||
| JP2016516020A5 (enExample) | ||
| JP2013543896A5 (enExample) | ||
| JP2017528503A5 (enExample) | ||
| JP2016511262A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2015526455A5 (enExample) | ||
| JP2017504635A5 (enExample) | ||
| JP2017527578A5 (enExample) | ||
| JP2016520618A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| JP2012533546A5 (enExample) | ||
| JP2012509263A5 (enExample) | ||
| JP2010501478A5 (enExample) | ||
| JP2010509356A5 (enExample) | ||
| JP2015526454A5 (enExample) | ||
| JP2011037901A5 (enExample) | ||
| JP2009531376A5 (enExample) | ||
| JP2014500265A5 (enExample) | ||
| JP2016507575A5 (enExample) | ||
| JP2018168191A5 (enExample) | ||
| JP2016510785A5 (enExample) | ||
| JP2010155827A5 (enExample) | ||
| HRP20151338T1 (hr) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita | |
| JP2012507535A5 (enExample) |